{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-034560","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.514819+00:00","generated_at":"2026-06-13T02:26:17.353267+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Monte Rosa appoints former Momenta CSO Anthony Manning to Board","bullets":["Board expanded from 8 to 9 directors; Dr. Manning fills newly created vacancy, effective July 25, 2023.","He will serve as a Class II director until the 2026 annual meeting of stockholders.","Board determined Manning is independent under Nasdaq listing standards.","Manning was CSO at Momenta Pharma, which was acquired by J&J for $6.5B in 2020; expertise in autoimmune disease and drug discovery.","He will receive cash and equity compensation per the company's non-employee director policy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-034560","json":"https://secwatch.observer/filing/0000950170-23-034560.json","markdown":"https://secwatch.observer/filing/0000950170-23-034560.md","text":"https://secwatch.observer/filing/0000950170-23-034560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/0000950170-23-034560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/glue-20230726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:26:17.353267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec4d4cb973","claim":"Anthony M. Manning was appointed as Director at Monte Rosa Therapeutics, Inc..","evidence_excerpt":"the Board appointed Anthony M. Manning, Ph.D. to fill the newly created vacancy on the Board resulting from an increase in the size of the Board from eight (8) to nine (9) directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017023034560/0000950170-23-034560-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}